Roche Finance Report 2013-PDF Free Download

https://www.roche.com/fb13e.pdf

>>Roche Finance Report 2013-PDF Free Download Pdf [Fast DOWNLOAD]<<


Related Books

Roche Finance Report 2013

Roche Finance Report 2013

Finance – 2013 in brief Roche in 2013 The Roche Group reported strong overall results in 2013. Core operating profit grew ahead of sales, and core earnings per share increased by 10% at constant exchange rates (CER).

Continue Reading...
Finance Report 2014 - Roche

Finance Report 2014 - Roche

2013 Key results Sales CER growth % 43.6 44.4 19.5 20.8 37.2 38.3 Core operating profit margin, % of sales Diagnostics Group 2014 2013 2014 2013 2014 2013 % change % of sales (mCHF) (mCHF) (CHF) (CER) 2014 2013 IFRS results Sales 47,462 46,780 +1 +5 Operating profit 14,090 16,376 –14 –9 29.7 35.0 Net income 9,535 11,373 –16 –10 20.1 24.3 Net income attributable to Roche shareholders ...

Continue Reading...
Roche Finance Report 2012

Roche Finance Report 2012

Finance – 2012 in brief Roche in 2012 The Roche Group reported strong overall results in a challenging market in 2012. Core operating profit grew ahead of sales, and Core Earnings per Share increased by 10% at constant exchange

Continue Reading...
Roche als Annual Report 2013 - Erhvervsstyrelsen

Roche als Annual Report 2013 - Erhvervsstyrelsen

Roche als Annual report 2013 Registration No.252305 15 Cash and cashequivalents Cashand cashequivalents comprise cashand short-term marketable securities withaterm of three months orlesswhich aresubjecttoaninsignificant riskofchanges invalue. Provisions Provision comprise anticipated costsrelated tosalesreturn, restructurings etc.Provisions are recognized when, as a result of past events, the ...

Continue Reading...
Finance Report 2016 - Roche

Finance Report 2016 - Roche

Roche Finance Report 2016 | 3 Financial Review | Roche Group Financial Review Roche Group results 2016 2015 2014 +4.0 +5.3 +4.9 Sales in billions of CHF % CER growth ...

Continue Reading...
Who we are Annual Report - Roche

Who we are Annual Report - Roche

Finance Report, and there have been no significant . changes in scope in 2016 compared to 2015. Reporting in accordance with the latest GRI . guidelines Since 2014, we have followed the GRI G4 guidelines (Global Reporting Initiative), with disclosure at core application level. We also report a number of additional

Continue Reading...
2013 ANNUAL REPORT - APICS

2013 ANNUAL REPORT - APICS

2013 ANNUAL REPORT. 2 2013 AUAL REPRT APICS MISSION APICS builds and validates knowledge in supply chain and operations management. We enable our community of members, affiliates, and customers to lead in the global marketplace. 3 2013 AUAL REPRT LETTER FROM APICS LEADERSHIP Global. Strategic. Responsive. These three words guide APICS, reflecting the multinational, crucial and ever-changing ...

Continue Reading...
Annual Report 2013 - GSK

Annual Report 2013 - GSK

GSK Annual Report 2013 3. Strategic report CEO’s review Our CEO’s Review of the year Company performance in 2013 was defined by remarkable output from our R&D organisation Over the past six years we have been making fundamental changes at GSK to deliver innovation and access to our products for patients and customers, and improved sustainable financial performance for our shareholders. In ...

Continue Reading...
SMITH & NEPHEW ANNUAL REPORT 2013 CORPORATE GOVERNANCE

SMITH & NEPHEW ANNUAL REPORT 2013 CORPORATE GOVERNANCE

Finance positions in all areas of the healthcare value chain including commercial, operations, R&D and business development. Nationality British Roberto Quarta (64) Independent Non-executive Director and Chairman Elect Roberto was appointed Non-executive Director and Chairman Elect on 4 December 2013. He is a member of the Nomination & Governance Committee. Roberto has signi ² cant management ...

Continue Reading...
ANNUAL REPORT 2013 - Novartis

ANNUAL REPORT 2013 - Novartis

6 novarTis group annual reporT 2013 Joerg reinhardt Dear sHareHoLDer, novartis achieved another strong operating result in 2013 and reinforced its leadership position as a diversified global healthcare company. ith the launch of innovative w therapies, a clear focus on growth markets, and productivity-oriented cost control, we increased sales and net in come at constant currency exchange rates ...

Continue Reading...
ANNUAL REPORT - PetroChina

ANNUAL REPORT - PetroChina

report and that there are no material omissions from, or misrepresentation or misleading statements contained in this annual report, and jointly and severally accept full responsibility thereof. This annual report has been approved at the first meeting of the Board of Directors in 2018. Mr. Yu Baocai, a non-executive Director and Mr. Duan Liangwei, a non-executive Director were absent from the ...

Continue Reading...